MAM
Mondelez India spreads the Valentine’s feeling, yet again!
MUMBAI: Mondelez India, the makers, and bakers of some of India’s iconic snacking brands, is all set to take over the season of love with special offerings from two of its most iconic brands Cadbury Dairy Milk Silk and OREO. Cadbury Dairy Milk Silk and Valentine's Day have been synonymous to each other for almost a decade capturing hearts with the "Say it with Silk" proposition. However, enhancing consumer experience one notch higher, the company will introduce some exciting offering under Oreo Cadbury Dipped and eCommerce, apart from the signature Cadbury Dairy Milk Silk ‘Heart Pop’ bar.
This year, the brand followed an unconventional path and reinvented the expression of love with the “How far will you go for love” campaign. A concept was conceived to nudge consumers to try and go beyond the usual and make it special for their partner this Valentine’s Day.
Commenting on the strategy for this Valentine’s Day, Mondelez India director marketing chocolates Anil Viswanathan said, “We have received great admiration with the pop your heart campaign over the couple of years and we are thrilled to take it into its third year. As leaders of the chocolate category in India, we attempt to identify new occasions and offer innovative ways for customers to convey their emotions with our products. These simple yet impactful ways help us to stay connected with our consumers. We hope our new heartwarming film and other exciting bundles on eCommerce will urge our consumers to go beyond their limits, for their loved ones, this Valentine’s Day.”
Joining the love wagon, this year OREO is taking forward its playful ritual to celebrate the spirit of love with Oreo Cadbury Dipped in its refreshed Valentine-inspired avatar to strike a chord with the youth. This latest offering from the house of OREO will be a digital-only campaign that will laud the sweet chocolatey and playful crunchy moments in every love story, just like the personality of Oreo Cadbury Dipped.
Speaking on the launch of the new packaging of Oreo Cadbury Dipped, Mondelez India associate director marketing biscuits Sudhanshu Nagpal said, “We launched Oreo Cadbury Dipped last year and it has been a phenomenal success story for us. The key reason it struck a chord with our audience is because consumers loved the fantastic combination of crunchy OREO and smooth chocolaty Cadbury. This year we are taking the narrative forward by celebrating this beautiful chocolaty crunchy love story in a fun playful way- through a packaging refresh and digital-first IMC. The key insight at the heart of this initiative is that a great love story is always an amalgamation of chocolatey romantic instances and crunchy playful moments. We strongly believe the product and insight will resonate with our consumers to share their ‘Crunchy, Chocolatey Love Story”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
